telomere repeat binding bouquet formation protein 2Genealiases: C15orf43 · SPGF59
Q-omics provides the consensus-scored TERB2 profile across patient tissues and cancer cell-line models. TERB2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TERB2 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, TERB2 RNA expression shows 9,052 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, THCA, and TGCT as cancer lineages where TERB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TERB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TERB2 survival associations across molecular data types. TERB2 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TERB2 RNA expression–survival associations across cancer types. High TERB2 expression shows unfavorable associations in CHOL, SKCM, KIRC and ACC, but favorable associations in LIHC and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TERB2 RNA expression.
This table summarizes TERB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TERB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TERB2 shows lower tumor expression in THCA, CHOL, LUSC, KIRC, LIHC and PRAD. The THCA box plot shows higher TERB2 RNA expression in normal versus tumor tissue (log2 FC = −0.153, t-test p < 0.001).
This table shows molecular features associated with TERB2 in patient tissues and cancer cell lines. In patient samples, TERB2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TERB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
